A Phase II Trial of Inotuzumab Ozogamicin Combined with Mini-HyperCVD as Salvage Therapy for Relapsed/Refractory ALL

Outcomes of relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) patients are poor. Inotuzumab ozogamicin (IO) is a CD22-monoclonal antibody bound to a toxin, calicheamicin. IO has single-agent activity in R/R ALL with an 80% response rate and median survival of 7.7 months. Adding IO to low-intensity chemotherapy might improve outcomes.

Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Rita Assi, Hagop Kantarjian, Farhad Ravandi, Susan Mary O'Brien, Partow Kebriaei, Nicholas J. Short, Deborah A. Thomas, Guillermo Garcia-Manero, Richard E. Champlin, Tapan M. Kadia, Jorge E. Cortes, Nitin Jain, Marina Konopleva, Rita Khouri, Zeev Estrov, Source Type: research